208 related articles for article (PubMed ID: 35186752)
1. FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.
Dolatabadi S; Jonasson E; Andersson L; Luna Santamaría M; Lindén M; Österlund T; Åman P; Ståhlberg A
Front Oncol; 2022; 12():816894. PubMed ID: 35186752
[TBL] [Abstract][Full Text] [Related]
2. The FUS-DDIT3 Interactome in Myxoid Liposarcoma.
Yu JSE; Colborne S; Hughes CS; Morin GB; Nielsen TO
Neoplasia; 2019 Aug; 21(8):740-751. PubMed ID: 31220736
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A
J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504
[TBL] [Abstract][Full Text] [Related]
4. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
[TBL] [Abstract][Full Text] [Related]
5. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
[No Abstract] [Full Text] [Related]
6. The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.
Zullow HJ; Sankar A; Ingram DR; Samé Guerra DD; D'Avino AR; Collings CK; Lazcano R; Wang WL; Liang Y; Qi J; Lazar AJ; Kadoch C
Mol Cell; 2022 May; 82(9):1737-1750.e8. PubMed ID: 35390276
[TBL] [Abstract][Full Text] [Related]
7. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
[TBL] [Abstract][Full Text] [Related]
8. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
[TBL] [Abstract][Full Text] [Related]
9. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
[TBL] [Abstract][Full Text] [Related]
10. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
[TBL] [Abstract][Full Text] [Related]
11. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma.
Berthold R; Isfort I; Erkut C; Heinst L; Grünewald I; Wardelmann E; Kindler T; Åman P; Grünewald TGP; Cidre-Aranaz F; Trautmann M; Fröhling S; Scholl C; Hartmann W
Oncogenesis; 2022 Apr; 11(1):20. PubMed ID: 35459264
[TBL] [Abstract][Full Text] [Related]
12. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms.
Downs-Kelly E; Goldblum JR; Patel RM; Weiss SW; Folpe AL; Mertens F; Hartke M; Tubbs RR; Skacel M
Am J Surg Pathol; 2008 Jan; 32(1):8-13. PubMed ID: 18162764
[TBL] [Abstract][Full Text] [Related]
13. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.
Bode-Lesniewska B; Frigerio S; Exner U; Abdou MT; Moch H; Zimmermann DR
Genes Chromosomes Cancer; 2007 Nov; 46(11):961-71. PubMed ID: 17647282
[TBL] [Abstract][Full Text] [Related]
14. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma.
Dolatabadi S; Jonasson E; Lindén M; Fereydouni B; Bäcksten K; Nilsson M; Martner A; Forootan A; Fagman H; Landberg G; Åman P; Ståhlberg A
Int J Cancer; 2019 Jul; 145(2):435-449. PubMed ID: 30650179
[TBL] [Abstract][Full Text] [Related]
15. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
Narendra S; Valente A; Tull J; Zhang S
Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
[TBL] [Abstract][Full Text] [Related]
16. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
[TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
18. Expression of DOL54 is not restricted to myxoid liposarcomas with the FUS-DDIT3 chimera but is found in various sarcomas.
Panagopoulos I; Mertens F; Isaksson M; Mandahl N
Oncol Rep; 2004 Jul; 12(1):107-10. PubMed ID: 15201968
[TBL] [Abstract][Full Text] [Related]
19. DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.
Scapa JV; Cloutier JM; Raghavan SS; Peters-Schulze G; Varma S; Charville GW
Am J Surg Pathol; 2021 Feb; 45(2):230-239. PubMed ID: 32815829
[TBL] [Abstract][Full Text] [Related]
20. Myxoid liposarcoma with cartilaginous differentiation showing
Suzuki K; Yasuda T; Watanabe K; Hori T; Kanamori M; Kimura T
Oncol Lett; 2017 Dec; 14(6):6789-6794. PubMed ID: 29181103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
